The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessAbstract
Glycemic management in type 2 diabetes mellitus has become increasingly complex and, to some extent, controversial, with a widening array of pharmacological agents now available,1–5 mounting concerns about their potential adverse effects and new uncertainties regarding the benefits of intensive glycemic control on macrovascular complications.6–9 Many clinicians are therefore perplexed as to the optimal strategies for their patients. As a consequence, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) convened a joint task force to examine the evidence and develop recommendations for antihyperglycemic therapy in nonpregnant adults with type 2 diabetes. Several guideline documents have been developed by members of these two organizations10 and by other societies and federations.2,11–15 However, an update was deemed necessary because of contemporary information on the benefits/risks of glycemic control, recent evidence concerning efficacy and safety of several new drug classes,16,17 the withdrawal/restriction of others, and increasing calls for a move toward more patient-centered care.18,19 This statement has been written incorporating the best available evidence and, where solid support does not exist, using the experience and insight of the writing group, incorporating an extensive review by additional experts (acknowledged below). The document refers to glycemic control; yet this clearly needs to be pursued within a multifactorial risk reduction framework. This stems from the fact that patients with type 2 diabetes are at increased risk of cardiovascular morbidity and mortality; the aggressive management of cardiovascular risk factors (blood pressure and lipid therapy, antiplatelet treatment, and smoking cessation) is likely to have even greater benefits. View this table: Table 1. Properties of Currently Available Glucose-Lowering Agents That May Guide Treatment Choice in Individual Patients With Type 2 Diabetes Mellitus These recommendations should be considered within the context …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Crossing the Quality Chasm: A New Health System for the 21st Century
Committee on Quality of Health Care in America (2002) · Journal For Healthcare Quality · doi:10.1111/j.1945-1474.2002.tb00463.x · Cited by 8,483
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Park, Y.-W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.427 · Cited by 2,074
Boulé, N. G., Haddad, E., Kenny, G. P., Wells, G. A., & Sigal, R. J. (2001) · JAMA · doi:10.1001/jama.286.10.1218 · Cited by 1,889
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Bantle (2008) · doi:10.2337/dc08-s061 · Cited by 1,795
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Thomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Self-citationSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Self-citationZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citationA self-regulation program for maintenance of weight loss
Wing, R. R., Tate, D. F., Gorin, A. A., Raynor, H. A., & Fava, J. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061883 · Cited by 830
Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Booth, G. L., Kapral, M. K., Fung, K., & Tu, J. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68967-8 · Cited by 783
Guyatt, G. H., Haynes, R. B., Jaeschke, R. Z., Cook, D. J., Green, L., Naylor, C. D., Wilson, M. C., Richardson, W. S., & for the Evidence-Based Medicine Working Group (2000) · JAMA · doi:10.1001/jama.284.10.1290 · Cited by 748
We need minimally disruptive medicine
May, C., Montori, V. M., & Mair, F. S. (2009) · BMJ · doi:10.1136/bmj.b2803 · Cited by 734
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Self-citationLago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Elmer, P. J., Obarzanek, E., Vollmer, W. M., Simons-Morton, D., Stevens, V. J., Young, D. R., Lin, P.-H., Champagne, C., Harsha, D. W., Svetkey, L. P., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-7-200604040-00007 · Cited by 596
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
UK prospective diabetes study (UKPDS): VIII. Study design, progress and performance
UK Prospective Diabetes Study Group (1991) · Diabetologia · doi:10.1007/bf00400195 · Cited by 543
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Self-citationKlein, S., Sheard, N. F., Pi-Sunyer, X., Daly, A., Wylie-Rosett, J., Kulkarni, K., & Clark, N. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2067 · Cited by 540
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Epidemiology and Natural History of NAFLD and NASH
Ong, J. P., & Younossi, Z. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.009 · Cited by 457
Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies
Anderson, J. W., Kendall, C. W. C., & Jenkins, D. J. A. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719316 · Cited by 448
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435
Self-citationUse of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Self-citationIndividualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I. B., Inzucchi, S. E., & Genuth, S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00007 · Cited by 386
Self-citationLamanna, C., Monami, M., Marchionni, N., & Mannucci, E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01349.x · Cited by 364
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Glycemic Control, Complications, and Death in Older Diabetic Patients
Huang, E. S., Liu, J. Y., Moffet, H. H., John, P. M., & Karter, A. J. (2011) · Diabetes Care · doi:10.2337/dc10-2377 · Cited by 343
Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes
Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., Gomis, R., & for the AT.LANTUS Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1282 · Cited by 314
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305
Bantle, J. P., Wylie-Rosett, J., Albright, A. L., Apovian, C. M., Clark, N. G., Franz, M. J., Hoogwerf, B. J., Lichtenstein, A. H., Mayer-Davis, E., Mooradian, A. D., et al. (2008) · University Libraries (University of Maryland) · doi:10.13016/f2uw-dtxz · Cited by 297
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Self-citationThe Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial
Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J. H., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebel, R. J., Yawn, B. P., Yapuncich, V., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.293 · Cited by 283
Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
DeFronzo, R. A. (2011) · Diabetes Care · doi:10.2337/dc11-0064 · Cited by 257
Patient-Important Outcomes in Registered Diabetes Trials
Gandhi, G. Y. (2008) · JAMA · doi:10.1001/jama.299.21.2543 · Cited by 252
Loke, Y. K., Kwok, C. S., & Singh, S. (2011) · BMJ · doi:10.1136/bmj.d1309 · Cited by 245
Triple Therapy in Type 2 Diabetes
Rosenstock, J., Sugimoto, D., Strange, P., Stewart, J. A., Soltes-Rak, E., Dailey, G., & on behalf of the Insulin Glargine 4014 Study Investigators (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-0695 · Cited by 235
Avilés-Santa, L., Sinding, J., & Raskin, P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00004 · Cited by 225
Effectiveness of Lifestyle Interventions for Individuals With Severe Obesity and Type 2 Diabetes
Unick, J. L., Beavers, D., Jakicic, J. M., Kitabchi, A. E., Knowler, W. C., Wadden, T. A., Wing, R. R., & for the Look AHEAD Research Group (2011) · Diabetes Care · doi:10.2337/dc11-0874 · Cited by 218
Gaziano, J. M., Cincotta, A. H., O'Connor, C. M., Ezrokhi, M., Rutty, D., Ma, Z. J., & Scranton, R. E. (2010) · Diabetes Care · doi:10.2337/dc09-2009 · Cited by 213
New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 187
Self-citationAdjust to Target in Type 2 Diabetes
Bergenstal, R. M., Johnson, M., Powers, M. A., Wynne, A., Vlajnic, A., Hollander, P., & Rendell, M. (2008) · Diabetes Care · doi:10.2337/dc07-2137 · Cited by 181
Self-citationThe Stunned β Cell: A Brief History
Ferrannini, E. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.009 · Cited by 175
Self-citationGreenfield, S., Billimek, J., Pellegrini, F., Franciosi, M., De Berardis, G., Nicolucci, A., & Kaplan, S. H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-12-200912150-00005 · Cited by 170
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
Self-citationContraindications can damage your health—is metformin a case in point?
Holstein, A., & Stumvoll, M. (2005) · Diabetologia · doi:10.1007/s00125-005-0026-1 · Cited by 165
Gross, J. L., Kramer, C. K., Leitão, C. B., Hawkins, N., Viana, L. V., Schaan, B. D., Pinto, L. C., Rodrigues, T. C., Azevedo, M. J., & for the Diabetes and Endocrinology Meta-analysis Group (DEMA)* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-10-201105170-00007 · Cited by 151
The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence
Nordin, C. (2010) · Diabetologia · doi:10.1007/s00125-010-1752-6 · Cited by 145
Chen, K.-W., Boyko, E. J., Bergstrom, R. W., Leonetti, D. L., Newell‐Morris, L. L., WAHL, P. W., & Fujimoto, W. Y. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.747 · Cited by 144
Initiate Insulin by Aggressive Titration and Education (INITIATE)
Yki-Järvinen, H., Juurinen, L., Alvarsson, M., Bystedt, T., Caldwell, I., Davies, M., Lahdenperä, S., Nijpels, G., & Vähätalo, M. (2007) · Diabetes Care · doi:10.2337/dc06-1357 · Cited by 139
The Relationship Between Glycemic Control and Falls in Older Adults
Nelson, J. M., Dufraux, K., & Cook, P. F. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01430.x · Cited by 138
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
Tahrani, A. A., Varughese, G. I., Scarpello, J. H., & Hanna, F. W. F. (2007) · BMJ · doi:10.1136/bmj.39255.669444.ae · Cited by 138
Diabetes Medications Related to an Increased Risk of Falls and Fall-Related Morbidity in the Elderly
Berlie, H. D., & Garwood, C. L. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m551 · Cited by 134
Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Bryan, J., Crane, A. M., Vila‐Carriles, W. H., Babenko, A. Y., & Aguilar‐Bryan, L. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054546879 · Cited by 133
Overview of Newer Agents: Where Treatment Is Going
DeFronzo, R. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.008 · Cited by 132
Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130
Incretin mimetics as a novel therapeutic option for hepatic steatosis
Tushuizen, M. E., Bunck, M. C. M., Pouwels, P. J. W., van Waesberghe, J. H. T., Diamant, M., & Heine, R. J. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01315.x · Cited by 127
Self-citationKoro, C. E., Lee, B. H., & Bowlin, S. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.10.020 · Cited by 126
Where Is the Patient in Diabetes Performance Measures?
Glasgow, R. E., Peeples, M., & Skovlund, S. E. (2008) · Diabetes Care · doi:10.2337/dc07-1845 · Cited by 125
de Laar, F. A. V., Lucassen, P. L., Akkermans, R., van de Lisdonk, E. H., & Grauw, W. J. D. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005061.pub2 · Cited by 119
Davis, T. M. E., Wright, A. D., Mehta, Z., Cull, C. A., STRATTON, I. M., Bottazzo, G. F., Bosi, E., Mackay, I. R., & Holman, R. R. (2005) · Diabetologia · doi:10.1007/s00125-005-1690-x · Cited by 118
Gerich, J., Raskin, P., Jean-Louis, L., Purkayastha, D., & Baron, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2093 · Cited by 116
Sluik, D., Boeing, H., Montonen, J., Pischon, T., Kaaks, R., Teucher, B., Tjønneland, A. M., Halkjær, J., Berentzen, T. L., Overvad, K., et al. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr048 · Cited by 115
Management of type 2 diabetes: summary of updated NICE guidance
Home, P., Mant, J., Diaz, J., & Turner, C. (2008) · BMJ · doi:10.1136/bmj.39560.442095.ad · Cited by 108
Davidson, M. B., Raskin, P., Tanenberg, R. J., Vlajnic, A., & Hollander, P. (2011) · Endocrine Practice · doi:10.4158/ep10323.or · Cited by 107
Incretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 107
Self-citationSmith, R. J., Nathan, D. M., Arslanian, S. A., Groop, L., Rizza, R. A., & Rotter, J. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1966 · Cited by 102
Owens, D. R., Luzio, S. D., Sert-Langeron, C., & Riddle, M. C. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01459.x · Cited by 99
Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B. H., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R. W., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 98
Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?
Nye, H. J., & Herrington, W. G. (2011) · Nephron Clinical Practice · doi:10.1159/000323739 · Cited by 92
Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy
Masoudi, F. A., & Inzucchi, S. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.013 · Cited by 89
Self-citationAcarbose: oral antidiabetes drug with additional cardiovascular benefits
Hanefeld, M., & Schaper, F. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.2.153 · Cited by 87
Current treatment of non‐alcoholic fatty liver disease
Ahmed, M. H., & Byrne, C. D. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00926.x · Cited by 84
Ilag, L. L., Kerr, L., Malone, J. K., & Tan, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.003 · Cited by 84
Blonde, L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.005 · Cited by 81
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
Singh‐Franco, D., Robles, G. I., & Gazze, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.04.005 · Cited by 76
Goals of Glycemic Control in Frail Older Patients With Diabetes
Lee, S. J., & Eng, C. (2011) · JAMA · doi:10.1001/jama.2011.404 · Cited by 71
Riveline, J., Danchin, N., Ledru, F., Varroud-Vial, M., & Charpentier, G. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70030-7 · Cited by 70
Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Bergenstal, R. M., Bailey, C. J., & Kendall, D. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.017 · Cited by 70
Self-citationMurad, M. H., Shah, N. D., Houten, H. K. V., Ziegenfuss, J. Y., Deming, J. R., Beebe, T. J., Smith, S. A., Guyatt, G. H., & Montori, V. M. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.08.005 · Cited by 69
Roberts, V. L., Stewart, J. A., Issa, M., Lake, B., & Melis, R. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.017 · Cited by 68
Treatment of Patients Over 64 Years of Age With Type 2 Diabetes
Prato, S. D., Heine, R. J., Keilson, L., Guitard, C., Shen, S. G., & Emmons, R. P. (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2075 · Cited by 64
Akalin, S., Berntorp, K. E., Ceriello, A., Das, A. K., Kilpatrick, E. S., Koblik, T., Munichoodappa, C., Pan, C., Rosenthall, W., Shestakova, M. V., et al. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02165.x · Cited by 60
Review article: Thiazolidinediones and heart failure
Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109338772 · Cited by 57
Translating Comparative Effectiveness Into Practice: The Case of Diabetes Medications
Shah, N. D., Mullan, R. J., Breslin, M., Yawn, B. P., Ting, H. H., & Montori, V. M. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181d5956c · Cited by 54
N of 1 trials in diabetes: making individual therapeutic decisions
Τσάπας, Α., & Matthews, D. R. (2008) · Diabetologia · doi:10.1007/s00125-008-0983-2 · Cited by 53
Self-citation7 Insulin action and substrate competition
Groop, L., & Ferrannini, E. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80243-5 · Cited by 51
Self-citationGordon, N. F., Salmon, R. D., Franklin, B. A., Sperling, L. S., Hall, L. K., Leighton, R. F., & Haskell, W. L. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.039 · Cited by 49
Davidson, J. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0469 · Cited by 46
Jabbour, S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01757.x · Cited by 44
Matthews, D. R., Τσάπας, Α., & Τσάπας, Α. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.036 · Cited by 44
Self-citationRaccah, D. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00846.x · Cited by 40
Intensified glucose control in type 2 diabetes—whose agenda?
Yudkin, J. S., Richter, B., & Gale, E. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61112-9 · Cited by 39
Strowig, S. M., & Raskin, P. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00440.x · Cited by 38
Counterpoint: Intensive Glucose Control and Mortality in ACCORD—Still Looking for Clues
Riddle, M. C. (2010) · Diabetes Care · doi:10.2337/dc10-1658 · Cited by 37
The Treat-to-Target Trial and Related Studies
Riddle, M. C. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.71 · Cited by 29
Bell, D. S. H., Dharmalingam, M., Kumar, S., & Sawakhande, R. B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01408.x · Cited by 28
Sulistio, M. S., Carothers, C., Mangat, M., Lujan, M., OLIVEROS, R. A., & CHILTON, R. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0015-9 · Cited by 25
Monogenic diabetes: implications for therapy of rare types of disease
Malecki, M. T., & Mlynarski, W. M. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00736.x · Cited by 23
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
Simonson, G., Cuddihy, R. M., Reader, D., & Bergenstal, R. M. (2011) · Diabetes Management · doi:10.2217/dmt.10.22 · Cited by 21
Self-citationConsensus guidelines, algorithms and care of the individual patient with type 2 diabetes
Nolan, J. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1767-z · Cited by 20
Individualizing treatment targets in diabetes care
Buse, J. B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.230 · Cited by 18
Self-citationSevere iatrogenic hypoglycemia in type 2 diabetes mellitus
Cryer, P. E. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0355 · Cited by 16
The importance of titrating starting insulin regimens in patients with type 2 diabetes
Garber, A. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01138.x · Cited by 15
The combinatorics of medications precludes evidence-based algorithms for therapy
Rodbard, D. (2010) · Diabetologia · doi:10.1007/s00125-010-1904-8 · Cited by 8
Research works printed but not linked: 3
- Berard, 2008, Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada, Canadian Journal of Diabetes, 32, S1
- NICE, 2009, Type 2 Diabetes: The Management of Type 2 Diabetes: NICE Clinical Guideline 87
- Committee on Quality of Health Care in America, 2001, Institute of Medicine
Cited by
Colosia, A., Khan, S., & Palencia, R. (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s51325 · Cited by 369
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Sussman, J. B., Kent, D. M., Nelson, J. P., & Hayward, R. A. (2015) · BMJ · doi:10.1136/bmj.h454 · Cited by 143
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
Metadata
- Authors
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2012-08-01
- Volume
- 25
- Issue
- 3
- Pages
- 154-171
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- OpenAlex
- W2406523485
- Cited by
- 286
- References
- 137
- FWCI
- 21.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.